B. Kanapuru

发表

Patient-reported outcomes (PRO) in cancer trials submitted to the FDA from 2012-2015.

P. Kluetz, B. Kanapuru, H. Singh, 2017 .

W. Ershler, B. Kanapuru, S. Makipour, 2008, Seminars in hematology.

Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation.

R. Pazdur, G. Blumenthal, A. Farrell, 2020, Blood reviews.

Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement

P. Kluetz, B. Kanapuru, T. Gwise, 2021, Blood Cancer Journal.

Roadmap to 2030 for Drug Evaluation in Older Adults

J. Gurwitz, M. Pirmohamed, B. Radziszewska, 2021, Clinical pharmacology and therapeutics.

Chapter 13 – Chemotherapy-Induced Myelosuppression in the Elderly

W. Ershler, B. Kanapuru, J. Yates, 2012 .

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials

L. Fashoyin-Aje, R. Pazdur, P. Kluetz, 2022, Blood advances.

B. King-Kallimanis, G. Blumenthal, M. Theoret, 2018, Seminars in oncology.

Proteasome inhibitor‐associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature

P. Waldron, B. Kanapuru, Afrouz Nayernama, 2020, American journal of hematology.

Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop.

L. Minasian, E. Basch, C. Cleeland, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration.

L. Fashoyin-Aje, R. Pazdur, Geoffrey Kim, 2017 .

Physiological Consequences of Aging

W. Ershler, B. Kanapuru, 2009 .

DECREASED CANCER PREVALENCE IN THE NURSING HOME

W. Ershler, B. Kanapuru, D. Muller, 2008, Journal of the American Geriatrics Society.

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

T. Pugh, D. Auclair, S. Lonial, 2021, Clinical Cancer Research.

Association of the red cell distribution width with red blood cell deformability.

K. Patel, W. Ershler, J. G. Mohanty, 2013, Advances in experimental medicine and biology.

Erythropoietin Deficiency and Late-Life Anemia

W. Ershler, B. Kanapuru, A. Artz, 2008 .

FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity.

L. Fashoyin-Aje, R. Pazdur, M. Theoret, 2023, Clinical lymphoma, myeloma & leukemia.

Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma

B. King-Kallimanis, J. Farley, D. Stenehjem, 2023, Quality of Life Research.

Is cancer incidence decreased in the frail elderly? Evidence from a prospective cohort study.

E. Simonsick, W. Ershler, B. Kanapuru, 2013, Journal of geriatric oncology.

FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.

R. Pazdur, M. Theoret, B. Kanapuru, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inflammation, coagulation, and the pathway to frailty.

W. Ershler, B. Kanapuru, 2009, The American journal of medicine.

FDA analysis of MRD data in hematologic malignancy applications.

Amy McKee, R. Pazdur, A. Farrell, 2017 .

Long-term survival of older breast cancer patients: population-based estimates over three decades

A. Jemal, W. Ershler, B. Kanapuru, 2012, Breast Cancer Research and Treatment.

FDA Analysis of Survival Outcomes in Older Adults with Relapsed-Refractory Multiple Myeloma (RRMM) Treated with Novel Drug Regimens

R. Pazdur, R. Sridhara, A. Farrell, 2019, Blood.

Multiple myeloma in the very old: an IASIA conference report.

H. Cohen, D. Longo, S. Tuchman, 2014, Journal of the National Cancer Institute.

Perspectives on Drug Development in Multiple Myeloma—Looking Forward to 2025

A. Jakubowiak, R. Pazdur, Shaji K. Kumar, 2021, Clinical Cancer Research.

Extreme body mass index and survival in newly diagnosed multiple myeloma patients

D. Auclair, S. Devlin, A. Lesokhin, 2023, Blood Cancer Journal.

Commentary multiple myeloma in the Very old: an IaSIa Conference report

S. Tuchman, A. Dispenzieri, B. Kanapuru, 2014 .

Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty.

B. King-Kallimanis, P. Kluetz, B. Kanapuru, 2023, Journal of geriatric oncology.

Multiple myeloma in the very old: an IASIA conference report.

H. Cohen, D. Longo, S. Tuchman, 2014, Journal of the National Cancer Institute.